AdeTherapeutics
AdeTherapeutics technology has been in-licensed by Temple Therapeutics. It uses a novel mechanism of action in wound healing to prevent or reduce surgical scarring. The products add significant value to patients, surgeons and potentially reduce costly hospital readmissions due to adhesion-related complications. The opportunity is to set standard of care and be the preferred choice for surgeons to prevent adhesions in gynaecology, general surgery, neurosurgery and ophthalmology.